These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30967968)

  • 1. Ceftolozane/Tazobactam Susceptibility Testing in Extended-Spectrum Betalactamase- and Carbapenemase-Producing Gram-Negative Bacteria of Various Clonal Lineages.
    Pazzini C; Ahmad-Nejad P; Ghebremedhin B
    Eur J Microbiol Immunol (Bp); 2019 Mar; 9(1):1-4. PubMed ID: 30967968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland.
    Saran O; Sulik-Tyszka B; Basak GW; Wróblewska MM
    Med Sci Monit; 2019 Jan; 25():305-311. PubMed ID: 30628586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    García-Fernández S; García-Castillo M; Bou G; Calvo J; Cercenado E; Delgado M; Pitart C; Mulet X; Tormo N; Mendoza DL; Díaz-Regañón J; Cantón R;
    Int J Antimicrob Agents; 2019 May; 53(5):682-688. PubMed ID: 30769199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-resistant profile and prevalence of extended spectrum β-lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia.
    Beyene D; Bitew A; Fantew S; Mihret A; Evans M
    PLoS One; 2019; 14(9):e0222911. PubMed ID: 31553773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 7. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
    J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016.
    Kuo SC; Liu CE; Lu PL; Chen YS; Lu MC; Ko WC; Hsueh PR; Chuang YC; Wang FD;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105883. PubMed ID: 31923574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010).
    Cantón R; Loza E; Aznar J; Calvo J; Cercenado E; Cisterna R; Romo FG; Hontangas JL; Calvo CR; Barrenechea AI; Tubau F; Weber I; Yuste P; Cavanillas R;
    Rev Esp Quimioter; 2011 Dec; 24(4):223-32. PubMed ID: 22173194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
    Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.
    Castanheira M; Doyle TB; Mendes RE; Sader HS
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
    Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
    J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Investigation of Plasmid Mediated mcr Colistin Resistance Gene in Clinical Enterobacterales Isolates].
    Özkaya E; Buruk CK; Tosun İ; Toraman B; Kaklıkkaya N; Aydın F
    Mikrobiyol Bul; 2020 Apr; 54(2):191-202. PubMed ID: 32723275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended spectrum beta-lactamase and metallo beta-lactamase production among Escherichia coli and Klebsiella pneumoniae isolated from different clinical samples in a tertiary care hospital in Kathmandu, Nepal.
    Nepal K; Pant ND; Neupane B; Belbase A; Baidhya R; Shrestha RK; Lekhak B; Bhatta DR; Jha B
    Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):62. PubMed ID: 28927454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
    J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.